Top

Cancer Chemotherapy and Pharmacology

Published in:

01-06-2015 | Original Article

Functional polymorphisms of ITGB1 are associated with clinical outcome of Chinese patients with resected colorectal cancer

Authors: Feng Zhou, Xiaojun Huang, Zhaohui Zhang, Yibing Chen, Xiaonan Liu, Jinliang Xing, Xianli He

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2015

Abstract

Purpose

Integrin β1 (ITGB1) has been recognized to play a major role in tumor growth, invasion and metastasis. However, effects of single-nucleotide polymorphisms (SNPs) in ITGB1 gene on the prognosis of patients with colorectal cancer (CRC) have not been reported.

Methods

A total of 372 patients with resected colorectal adenocarcinoma were enrolled in our study. Three functional SNPs (rs2230395, rs1187075 and rs1187076) in ITGB1 were selected and genotyped using the Sequenom iPLEX genotyping system.

Results

We identified two SNPs (rs2230395 and rs1187075) in ITGB1 gene to be significantly associated with CRC overall survival (OS). Compared with the homozygous wild-type (AA) and heterozygous variant (AC), rs2230395 homozygous variant (CC) conferred a 1.55-fold (95 % CI 1.00–2.41, P = 0.049) increased risk of death. Similar result was obtained for homozygous variant (AA) in rs1187075 with a 1.62-fold (95 % CI 1.08–2.42, P = 0.020). In stratified analysis, this association in rs2230395 remained to be significant in patients receiving chemotherapy, but not in those without chemotherapy. We further evaluated the effects of chemotherapy on CRC survival in subgroups stratified by rs2230395 and rs1187075 genotypes. We found that chemotherapy resulted in a significantly better OS in patients with the homozygous wild-type (WW) or heterozygous variant (WV) genotype in both rs2230395 and rs1187075 when compared with patients with homozygous variant (VV) genotype.

Conclusions

Our data suggest that ITGB1 SNPs might be a prognostic biomarker for CRC patients, especially in those receiving chemotherapy. Our findings warrant validation in larger independent populations.

Available only for authorised users

Cox D, Brennan M, Moran N (2010) Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9:804–820CrossRefPubMed

Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687CrossRefPubMed

Guo L, Zhang F, Cai Y, Liu T (2009) Expression profiling of integrins in lung cancer cells. Pathol Res Pract 205:847–853CrossRefPubMed

Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ (1997) Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33:263–271CrossRefPubMed

Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope CG, Risberg B, Kopolovic J (2003) AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90:248–257CrossRefPubMed

Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE (2009) Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 8:499–508CrossRefPubMedCentralPubMed

Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535CrossRefPubMedCentralPubMed

Huck L, Pontier SM, Zuo DM, Muller WJ (2010) Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 107:15559–15564CrossRefPubMedCentralPubMed

Kren A, Baeriswyl V, Lehembre F, Wunderlin C, Strittmatter K, Antoniadis H, Fassler R, Cavallaro U, Christofori G (2007) Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO J 26:2832–2842CrossRefPubMedCentralPubMed

10.

dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrao EI (2012) Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol 7:104CrossRefPubMedCentralPubMed

11.

Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C (2007) Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67:659–664CrossRefPubMed

12.

Zhang PF, Zeng GQ, Yi LZ, Liu JP, Wan XX, Qu JQ, Li JH, Li C, Tang CE, Hu R, Ye X, Chen Y, Chen ZC, Xiao ZQ (2013) Identification of integrin beta1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC-MS/MS combined with iTRAQ technology. Oncol Rep 30:341–349PubMed

13.

Pontes-Junior J, Reis ST, Bernardes FS, Oliveira LC, Barros EA, Dall’Oglio MF, Timosczuk LM, Ribeiro-Filho LA, Srougi M, Leite KR (2013) Correlation between beta1 integrin expression and prognosis in clinically localized prostate cancer. Int Braz J Urol 39:335–342. Discussion 343CrossRefPubMed

14.

Bottger TC, Maschek H, Lobo M, Gottwohl RG, Brenner W, Junginger T (1999) Prognostic value of immunohistochemical expression of beta-1 integrin in pancreatic carcinoma. Oncology 56:308–313CrossRefPubMed

15.

Howe GA, Addison CL (2012) Beta1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adh Migr 6:71–77CrossRefPubMedCentralPubMed

16.

Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics. CA Cancer J Clin 64:104–117CrossRefPubMed

17.

Shin A, Jung KW, Won YJ (2013) Colorectal cancer mortality in Hong Kong of China, Japan, South Korea, and Singapore. World J Gastroenterol 19:979–983CrossRefPubMedCentralPubMed

18.

Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C, Qu F, Li Y, Bao G, Chen Z, Xing J (2011) Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer 118:937–946CrossRefPubMed

19.

Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, Fu X, Palazzo JP, He X, Chen Z, Yang H (2011) Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev 21:217–227CrossRefPubMedCentralPubMed

20.

Dai J, Wan S, Zhou F, Myers RE, Guo X, Li B, Fu X, Palazzo JP, Dou K, Yang H, Xing J (2012) Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection. PLoS One 7:e34758CrossRefPubMedCentralPubMed

21.

Wang Y, Long L, Li T, Zhou Y, Jiang L, Zeng X, Dan H, Liao G, Luo G, Wang H, Zhou M, Xu Y, Li J, Chen Q (2014) Polymorphisms of microRNA-binding sites in integrin genes are associated with oral squamous cell carcinoma susceptibility and progression. Tohoku J Exp Med 233:33–41CrossRefPubMed

22.

Eun YG, Kim SK, Chung JH, Kwon KH (2013) Association study of integrins beta 1 and beta 2 gene polymorphism and papillary thyroid cancer. Am J Surg 205:631–635CrossRefPubMed

23.

Chow S-C, Wang H, Shao J (2003) Sample size calculations in clinical research. Biostatistics, vol 11. CRC Press

24.

Fan LF, Dong WG, Jiang CQ, Xia D, Liao F, Yu QF (2009) Expression of putative stem cell genes Musashi-1 and beta1-integrin in human colorectal adenomas and adenocarcinomas. Int J Colorectal Dis 25:17–23CrossRefPubMed

25.

Fujita S, Watanabe M, Kubota T, Teramoto T, Kitajima M (1995) Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett 91:145–149CrossRefPubMed

26.

Song J, Zhang J, Wang J, Cao Z, Guo X, Dong W. Beta1 integrin modulates tumor growth and apoptosis of human colorectal cancer. Oncol Rep 32:302–308

27.

Fujita S, Suzuki H, Kinoshita M, Hirohashi S (1992) Inhibition of cell attachment, invasion and metastasis of human carcinoma cells by anti-integrin beta 1 subunit antibody. Jpn J Cancer Res 83:1317–1326CrossRefPubMed

28.

Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA, Ginsberg MH (1997) Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88:521–530CrossRefPubMed

29.

Schlaepfer DD, Hunter T (1997) Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem 272:13189–13195CrossRefPubMed

30.

King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS (1997) Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 17:4406–4418PubMedCentralPubMed

31.

Fornaro M, Languino LR (1997) Alternatively spliced variants: a new view of the integrin cytoplasmic domain. Matrix Biol 16:185–193CrossRefPubMed

32.

Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR (1999) p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma. J Clin Invest 103:321–329CrossRefPubMedCentralPubMed

33.

Goel HL, Li J, Kogan S, Languino LR (2008) Integrins in prostate cancer progression. Endocr Relat Cancer 15:657–664CrossRefPubMedCentralPubMed

34.

Wittig BM, Goebel R, Weg-Remers S, Pistorius G, Feifel G, Zeitz M, Stallmach A (2001) Stage-specific alternative splicing of CD44 and alpha 6 beta 1 integrin in colorectal tumorigenesis. Exp Mol Pathol 70:96–102CrossRefPubMed

35.

Hudson TJ (2003) Wanted: regulatory SNPs. Nat Genet 33:439–440CrossRefPubMed

36.

Wang X, Tomso DJ, Liu X, Bell DA (2005) Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol Appl Pharmacol 207:84–90CrossRefPubMed

37.

Wray GA, Hahn MW, Abouheif E, Balhoff JP, Pizer M, Rockman MV, Romano LA (2003) The evolution of transcriptional regulation in eukaryotes. Mol Biol Evol 20:1377–1419CrossRefPubMed

38.

Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS (2001) Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98:1897–1903CrossRefPubMed

39.

Taylor ST, Hickman JA, Dive C (2000) Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 92:18–23CrossRefPubMed

40.

Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20:4995–5004CrossRefPubMed

41.

Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5:662–668CrossRefPubMed

42.

Rintoul RC, Sethi T (2002) Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 102:417–424CrossRef

43.

Desgrosellier JS, Cheresh DA (2009) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22CrossRef

44.

Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A, Tadano J, Sakai T, Yamamoto K (2002) Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 95:896–906CrossRefPubMed

45.

Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, Kitayama J, Takahashi K, Nagawa H (2011) CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the beta1-integrin signaling. J Surg Res 175:278–288CrossRefPubMed

46.

Brenner H, Kloor M, Pox CP (2013) Colorectal cancer. Lancet 383:1490–1502CrossRefPubMed

Title: Functional polymorphisms of ITGB1 are associated with clinical outcome of Chinese patients with resected colorectal cancer
Authors: Feng Zhou
Xiaojun Huang
Zhaohui Zhang
Yibing Chen
Xiaonan Liu
Jinliang Xing
Xianli He
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2745-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors

Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe

DNA intercalative 4-butylaminopyrimido[4′,5′:4,5]thieno(2,3-b)quinoline induces cell cycle arrest and apoptosis in leukemia cells

A phase I study of resminostat in Japanese patients with advanced solid tumors

Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer